📊 SBFMW Key Takeaways
Is Sunshine Biopharma Inc. (SBFMW) a Good Investment?
Sunshine Biopharma is fundamentally unprofitable with negative operating and net margins (-17.2% and -16.5% respectively), burning cash at $5.5M annually in free cash flow despite modest 4.1% revenue growth. While the company maintains strong liquidity (4.17x current ratio) and low debt (0.09x debt-to-equity), it has only ~18-20 months of cash runway at current burn rates, making near-term profitability achievement critical for survival.
Sunshine Biopharma Inc. Key Strengths (SBFMW)
- Strong short-term liquidity with 4.17x current ratio and $9.1M cash position
- Low leverage with 0.09x debt-to-equity ratio and only $7.0M total liabilities
- Reasonable gross margins at 33.8% indicating product pricing power
SBFMW Stock Risks: Sunshine Biopharma Inc. Investment Risks
- Negative operating cash flow of $5.3M and negative free cash flow of $5.5M—unsustainable burn rate
- Operating and net losses despite revenue growth suggest structural unprofitability and operating expense management issues
- Limited cash runway of approximately 18-20 months at current burn rate with no clear path to profitability
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low insider confidence in company direction
Key Metrics to Watch
- Operating cash flow trending—must turn positive for viability
- Revenue growth acceleration—4.1% YoY is insufficient to offset losses
- Operating expense ratio—must decline significantly to achieve profitability
- Cash burn rate and remaining runway—critical for assessing going concern risk
Sunshine Biopharma Inc. (SBFMW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.17x current ratio provides a solid financial cushion.
SBFMW Profit Margin, ROE & Profitability Analysis
SBFMW vs Healthcare Sector: How Sunshine Biopharma Inc. Compares
How Sunshine Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sunshine Biopharma Inc. Stock Overvalued? SBFMW Valuation Analysis 2026
Based on fundamental analysis, Sunshine Biopharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sunshine Biopharma Inc. Balance Sheet: SBFMW Debt, Cash & Liquidity
SBFMW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sunshine Biopharma Inc.'s revenue has grown significantly by 15,794% over the 5-year period, indicating strong business expansion. The most recent EPS of $-351.36 indicates the company is currently unprofitable.
SBFMW Revenue Growth, EPS Growth & YoY Performance
SBFMW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.1M | -$1.2M | N/A |
| Q3 2025 | $8.4M | -$883.8K | $-0.98 |
| Q2 2025 | $9.3M | -$494.3K | $-0.82 |
| Q1 2025 | $7.5M | -$1.2M | $-0.44 |
| Q3 2024 | $6.0M | -$651.5K | N/A |
| Q2 2024 | $5.6M | -$494.3K | N/A |
| Q1 2024 | $4.9M | -$1.3M | $-2.00 |
| Q3 2023 | $132.8K | -$651.5K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sunshine Biopharma Inc. Dividends, Buybacks & Capital Allocation
SBFMW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sunshine Biopharma Inc. (CIK: 0001402328)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SBFMW
What is the AI rating for SBFMW?
Sunshine Biopharma Inc. (SBFMW) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SBFMW's key strengths?
Claude: Strong short-term liquidity with 4.17x current ratio and $9.1M cash position. Low leverage with 0.09x debt-to-equity ratio and only $7.0M total liabilities.
What are the risks of investing in SBFMW?
Claude: Negative operating cash flow of $5.3M and negative free cash flow of $5.5M—unsustainable burn rate. Operating and net losses despite revenue growth suggest structural unprofitability and operating expense management issues.
What is SBFMW's revenue and growth?
Sunshine Biopharma Inc. reported revenue of $36.3M.
Does SBFMW pay dividends?
Sunshine Biopharma Inc. does not currently pay dividends.
Where can I find SBFMW SEC filings?
Official SEC filings for Sunshine Biopharma Inc. (CIK: 0001402328) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SBFMW's EPS?
Sunshine Biopharma Inc. has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SBFMW's fundamental grade?
Based on our AI fundamental analysis in May 2026, Sunshine Biopharma Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SBFMW stock overvalued or undervalued?
Valuation metrics for SBFMW: ROE of -25.9% (sector avg: 15%), net margin of -16.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SBFMW's AI grade for 2026?
Our dual AI analysis gives Sunshine Biopharma Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SBFMW's free cash flow?
Sunshine Biopharma Inc.'s operating cash flow is $-5.3M, with capital expenditures of $174.5K. FCF margin is -15.2%.
How does SBFMW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16.5% (avg: 12%), ROE -25.9% (avg: 15%), current ratio 4.17 (avg: 2).